Evidence map›Paper›PMID 41569198›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2026

Immunogenicity of Fetal Liver-Derived Progenitor and Stem Cells: Expression of MHC Molecules.

Denys Vatlitsov, Khrystyna Sorochynska, Alla Tkachenko, Nadiia Dovhopola, Mariya Klunnyk

Abstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Denys VatlitsovState Institution "National Research Center for Radiation Medicine, Hematology and Oncology of National Academy of Medical Sciences of Ukraine"; Laboratory of Molecular Biology of the Department of Clinical Immunology of the Institute of Clinical Radiology; Research and Development Laboratory, Limited Liability Company "Cell Therapy Center "EmCell", Kyiv, Ukraine.
Khrystyna SorochynskaStem Cell Bank CEO, Laboratory Department, Limited Liability Company "Cell Therapy Center "EmCell", Kyiv, Ukraine.
Alla TkachenkoBiotechnology Laboratory, Limited Liability Company "Cell Therapy Center "EmCell", Kyiv, Ukraine.
Nadiia DovhopolaResearch and Development Laboratory, Limited Liability Company "Cell Therapy Center "EmCell", Kyiv, Ukraine.
Mariya KlunnykClinical Department, Limited Liability Company "Embryonic Tissues Center "EmCell", Kyiv, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRegenerative medicine increasingly relies on stem cell-based therapies, yet their clinical success is largely determined by immunological compatibility. Fetal liver-derived progenitor and stem cells represent a promising, yet insufficiently characterized, source for transplantation.

objectiveThis study aimed to evaluate the immunogenicity of fetal liver cells by analyzing the expression of HLA class I and II molecules and detecting the presence of anti-HLA antibodies after cryopreservation at early gestational ages.

methodsCell suspensions were obtained from fetal livers at 5-12 weeks of gestation. Flow cytometry was performed using a CyFlow Space cytometer (Sysmex, Germany), and results were analyzed with Statistica 10. HLA class I (HLA-ABC) and class II (HLA-DR/DP/DQ) expression was quantified as the percentage of positive cells and their mean fluorescence intensity. Anti-HLA antibodies were assessed in the cell suspensions. Statistical analysis included descriptive statistics, group comparisons, and correlation analyses with gestational age.

resultsHLA class I expression was consistently detectable across all samples. In contrast, HLA class II expression increased progressively with gestational age, reflecting the developmental maturation of the fetal immune system. Importantly, these antigens primarily indicated differentiation toward myeloid lineages, which are unlikely to provoke graft-versus-host immune reactions. Anti-HLA antibodies were not detected in any of the analyzed suspensions.

conclusionsThis study provides the first systematic assessment of HLA expression in fetal liver-derived progenitor and stem cells following cryopreservation. The results suggest that these cells retain a favorable immunological profile, supporting their potential application in regenerative medicine. The findings highlight the importance of considering gestational age in evaluating immunogenicity. Further studies with larger sample sizes and in vivo validation are required to confirm clinical safety.

Indexed as

FetusHistocompatibility Antigens Class IHistocompatibility Antigens Class IILiverStem CellsCryopreservationFemaleGestational AgeHumansHistocompatibility Antigens Class IHistocompatibility Antigens Class IIfetal liver cellsHLA expressionimmunogenicityregenerative medicinestem cell therapy

Identifiers

PMID41569198
PMCPMC13418043

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.